These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa. Boomsma F; Meerwaldt JD; Man in't Veld AJ; Hovestadt A; Schalekamp MA J Neurol; 1989 May; 236(4):223-30. PubMed ID: 2760634 [TBL] [Abstract][Full Text] [Related]
23. Levodopa with benserazide or carbidopa in Parkinson disease. Rinne UK; Mölsä P Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221 [TBL] [Abstract][Full Text] [Related]
24. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa. Aarli JA; Gilhus NE Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767 [TBL] [Abstract][Full Text] [Related]
25. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients. Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074 [TBL] [Abstract][Full Text] [Related]
26. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. Tetrud J; Nausieda P; Kreitzman D; Liang GS; Nieves A; Duker AP; Hauser RA; Farbman ES; Ellenbogen A; Hsu A; Kell S; Khanna S; Rubens R; Gupta S J Neurol Sci; 2017 Feb; 373():116-123. PubMed ID: 28131167 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649 [TBL] [Abstract][Full Text] [Related]
29. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations. Hempel AG; Wagner ML; Maaty MA; Sage JI Ann Pharmacother; 1998 Sep; 32(9):878-83. PubMed ID: 9762373 [TBL] [Abstract][Full Text] [Related]
31. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar]. Kamenetskiĭ VK Klin Med (Mosk); 1984 Apr; 62(4):112-6. PubMed ID: 6737958 [No Abstract] [Full Text] [Related]
32. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047 [TBL] [Abstract][Full Text] [Related]
33. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. Ondo WG; Shinawi L; Moore S Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074 [TBL] [Abstract][Full Text] [Related]
34. Combined use of benserazide and carbidopa in Parkinson's disease. Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015 [TBL] [Abstract][Full Text] [Related]
35. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888 [TBL] [Abstract][Full Text] [Related]
36. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Block G; Liss C; Reines S; Irr J; Nibbelink D Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028 [TBL] [Abstract][Full Text] [Related]
37. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor]. Meco G; Casacchia M; Zamponi A; Agnoli A Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427 [No Abstract] [Full Text] [Related]
38. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Deleu D; Jacques M; Michotte Y; Ebinger G Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654 [TBL] [Abstract][Full Text] [Related]
39. Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone. Shan DE; Lee SJ; Chao LY; Yeh SI Can J Neurol Sci; 2001 Feb; 28(1):70-5. PubMed ID: 11252300 [TBL] [Abstract][Full Text] [Related]
40. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients. Kostić VS; Covicković-Sternić N Neurologija; 1990; 39(2):99-105. PubMed ID: 2267052 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]